Philogen SpAMIL:PHIL -0.21%61 Current Ratio is 7.76 as of Dec. 2025, which is 1% below its 10-year median of 7.86. GuruFocus rates MIL:PHIL with a GF Score™ of 61/100 and a GF Value™ of €227.22 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Philogen SpA ranks better than 71.4% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Philogen SpA's current ratio for the quarter that ended in Dec. 2025 was 7.76.
Philogen SpA has a current ratio of 7.76. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Philogen SpA's Current Ratio or its related term are showing as below:
MIL:PHIL'
s Current Ratio Range Over the Past 10 Years
Min: 5.3 Med: 7.86 Max: 9.35
Current: 7.76
During the past 6 years, Philogen SpA's highest Current Ratio was 9.35. The lowest was 5.30. And the median was 7.86.
MIL:PHIL's Current Ratio is ranked better than 71.4% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs MIL:PHIL: 7.76
Philogen SpA (MIL:PHIL) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Philogen SpA Current Ratio Related Terms
Philogen SpA Current Ratio Historical Data
* Premium members only.
The historical data trend for Philogen SpA's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:PHIL vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Philogen SpA's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Philogen SpA Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Philogen SpA's Current Ratio distribution charts can be found below:
* The bar in red indicates where Philogen SpA's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Philogen SpA (MIL:PHIL) has a Current Ratio of 7.76 as of Dec. 2025. This is near median its historical median of 7.86. Over the past decade, Philogen SpA's Current Ratio has ranged from 5.30 to 9.35. According to the industry distribution chart, Philogen SpA ranks #405 out of 1416 companies in the Biotechnology industry, placing it in the top 28.6%.
Is Philogen SpA's Current Ratio too high?
Philogen SpA's current Current Ratio of 7.76 is near median its 10-year median of 7.86. Over the past 10 years, this metric has ranged from a low of 5.30 to a high of 9.35. The Biotechnology industry median Current Ratio is 3.89. Philogen SpA's value of 7.76 is 99.7% above this industry median. Based on the distribution chart, Philogen SpA ranks #405 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Philogen SpA has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Philogen SpA's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Philogen SpA ranks #405 out of 1416 companies for Current Ratio. This puts Philogen SpA in the upper half of its industry. The industry median Current Ratio is 3.89. Philogen SpA's value of 7.76 is 99.7% above this benchmark. Historically, Philogen SpA's own Current Ratio has ranged from 5.30 to 9.35 over the past decade. While the company's 10-year median is 7.86 vs. the industry median of 3.89, Philogen SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Philogen SpA's current Current Ratio of 7.76 is 99.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Philogen SpA's current Current Ratio is 7.76, which is near median its own 10-year median of 7.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Philogen SpA stock overvalued right now?
Based on GuruFocus' analysis, Philogen SpA (MIL:PHIL) is currently considered Possible Value Trap. The stock's GF Value™ is €227.22, compared to a current price of €23.25 — trading 89.8% below its estimated fair value. The current Current Ratio is 7.76, which is near median its 10-year median of 7.86 and 99.7% above the Biotechnology industry median of 3.89. Philogen SpA's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Philogen SpA (MIL:PHIL), the current Current Ratio is 7.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Philogen SpA (MIL:PHIL) Overvalued in 2026?
Based on GuruFocus' analysis, Philogen SpA stock appears to be undervalued.
The current stock price of €23.25 is trading 89.8% below its estimated GF Value™ of €227.22.
GuruFocus considers Philogen SpA to be Possible Value Trap.
Key valuation signals for MIL:PHIL:
Current Ratio: 7.76 (near median its 10-year median of 7.86)
GF Value™: €227.22 vs. price of €23.25 (89.8% below fair value)
Industry Position: 99.7% above the Biotechnology median (#405 of 1416)
No single metric tells the full story. See the MIL:PHIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
61GF Score
Get the complete analysis for MIL:PHIL
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:PHIL has been successfully added to your 
